A study analyzing early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations
Latest Information Update: 01 Apr 2022
At a glance
- Drugs Axitinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
Most Recent Events
- 01 Apr 2022 New trial record
- 19 Feb 2022 Results presented at the 2022 Genitourinary Cancers Symposium